Participated · Seed · Jan 2026

Proxima (formerly VantAI) is building a platform that maps protein-protein interactions across the proteome and designs small-molecule drugs that modulate those interactions. Its NeoLink structural-proteomics system generates large-scale complex data, while the companion Neo AI model suite applies frontier machine-learning techniques to identify and design molecular glues, PROTACs, and other proximity-modulating compounds. The company focuses on expanding the druggable target space in oncology, immunology, and additional disease areas, aiming to improve safety and shorten development timelines for historically “undruggable” targets. Proxima has already secured multibillion-dollar research collaborations with Johnson & Johnson, Bristol Myers Squibb, and Blueprint Medicines (now part of Sanofi), with the first co-developed program expected to enter clinical trials in 2026. It maintains both an internal pipeline and extensive external partnerships to advance novel proximity therapeutics. Financially, the firm closed an oversubscribed $80 million seed round and benefits from the non-dilutive value of its large pharmaceutical collaborations. Headquartered in New York and Boston, Proxima is positioning its technology and data layer as foundational infrastructure for the next generation of AI-driven drug discovery.

Participated · Equity · Dec 2025

Relation combines artificial intelligence with experimental biology to discover and develop therapeutics across immunology, metabolic and bone disease indications. Led by CEO David Roblin, the company builds integrated AI and laboratory platforms that span the entire drug-development cycle, from target identification to clinical candidate optimization. Its current portfolio includes multiple programs in each of its three focus disease areas. The firm positions itself as a full-stack drug developer rather than a tool provider, aiming to bring proprietary medicines to market. Proceeds from its latest financing will be used to broaden operations and intensify R&D. No revenue, user, or clinical milestone metrics were disclosed in the article.

Participated · Series A · Oct 2025

Founded in 2022, San Francisco-based Weave Bio offers an end-to-end, AI-driven regulatory platform that helps pharmaceutical companies, biotech firms, CROs, and consultants create, manage, and submit complex regulatory dossiers. The software integrates AI across data extraction, authoring, review, publishing, and health-authority response workflows, cutting regulatory timelines by more than 50% while improving consistency and compliance. Initially adopted for pre-clinical IND filings, the platform now supports clinical, approval-stage, and post-market submissions and complies with FDA, EMA, and other global standards. Recent recognition includes winning the "Biotech AI Innovation of the Year" award. Future product plans include full coverage of NDA/BLA filings, deeper AI analytics for portfolio insights, and geographic expansion into Europe, Japan, and Latin America. The company will also grow its commercial team to reinforce market leadership. With the new Series A financing, Weave Bio’s total funding reaches $36 million, providing resources for accelerated product development and global scale-up.

Participated · Series A · May 2025

trawa is a Berlin-based electricity provider and AI-powered software company that optimizes energy procurement and management for mid-sized industrial and commercial businesses. The company combines all available market products, including direct power purchase agreements with solar and wind farms, with AI software that analyzes consumption profiles, identifies savings potential, and creates optimized energy portfolios. Its integrated B2B solution covers energy supply, energy management, and flexibility control. trawa serves more than 100 commercial customers across over 3,000 locations in Germany and has been active in Austria since the beginning of the year. Founded in 2022, it targets businesses with annual electricity costs of at least €100,000. The company plans to use the new funding to expand its integrated B2B offering and scale its procurement and management services. trawa offers an AI-powered platform that helps small and medium-sized enterprises buy and manage renewable electricity by combining downstream customer data with machine-learning-driven procurement. The platform optimizes mixes of power sources and staggers purchases to match consumption patterns, and its management software integrates onsite assets like rooftop solar and batteries. Trawa claims this combination can enable companies to save up to 30% of their energy costs annually. The idea was conceived by co-founder and CEO David Budde while at Bain and Company in response to post‑2022 energy market volatility and tightening regulation. The startup already serves industrial customers in the DACH region, including SETEX-Textil, Amano Hotel Group, Sunmaxx, Loxxess and Coroplast Group. Financially, trawa has raised capital to support growth, most recently closing a €10M seed round. trawa is a Berlin-based provider of an AI-powered platform that helps businesses procure renewable and affordable electricity. The platform analyzes customer consumption behavior and combines that data with appropriate electricity products to enable sustainable procurement. Founded in 2022 by David Budde, Max Lüddemann and Robert Quick, the company is currently applying for a license as an energy supplier. trawa raised €2.4M in a pre-seed round to support its growth. The company intends to use the funds to build its team and further develop its AI-based software.

Participated · Seed · Feb 2025

Terrain Biosciences builds tools and services to design and manufacture high-quality RNA for RNA therapeutics and vaccines. The company offers a catalog of commonly used sequences, custom RNA builds, and AI-guided sequence design tools to optimize sequences for safety, efficacy, and manufacturability. It leverages recent innovations in protein and RNA design and uses experimental data to train novel machine-learning models for RNA sequence design. Terrain positions its platform as a sandbox for scientists to design and build sequences faster and with higher confidence. The company says these capabilities support drug developers through every step of the journey to the clinic and beyond. It is led by CEO Chetan Tadvalkar and was founded by Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu.